Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma.
Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma.
复制标题
DOI：
10.3892/ijo.30.1.97
复制
发表时间：
2007
影响因子：
5.2
通讯作者：
H. Shimada;Mari Kuboshima;T. Shiratori;Y. Nabeya;A. Takeuchi;H. Takagi;F. Nomura;M. Takiguchi;T. Ochiai;T. Hiwasa
中科院分区：
文献类型：
--
作者：
H. Shimada;Mari Kuboshima;T. Shiratori;Y. Nabeya;A. Takeuchi;H. Takagi;F. Nomura;M. Takiguchi;T. Ochiai;T. Hiwasa
为了寻找新的食管鳞状细胞癌（SCC）血清学标志物，我们应用重组cDNA表达克隆（SEREX）技术对SCC抗原进行了血清学鉴定。E.用从食管癌细胞系（T.Tn）的mRNA制备的噬菌体cDNA文库转化大肠杆菌，并筛选IPTG诱导的cDNA产物与食管SCC患者同种异体血清中的抗体的相互作用。我们确定了肌巨蛋白（MMGL，磷酸二酯酶4D相互作用蛋白/PDE 4DIP）作为一种新的SEREX抗原食管SCC。Western blot分析显示，血清抗-myomegalin抗体（s-MMGL-Abs）存在于43（47%）的91例患者，但只有一个（2.2%）的45名健康对照。在21例I期疾病患者中，8例（38%）血清学阳性。s-MMGL-Abs的阳性率高于其他常规肿瘤标志物。逆转录-PCR分析表明，从肌巨蛋白变体1到变体5的选择性剪接可以部分解释s-MMGL-Ab的发展。虽然s-MMGL-Abs的存在与患者的任何临床病理特征无关，但多变量分析表明s-MMGL-Abs的存在与良好的预后显著相关。因此，s-MMGL-Abs可能是一个有用的肿瘤标志物，以诊断和建立食管鳞癌患者的预后。
In order to identify new serum markers of esophageal squamous cell carcinoma (SCC), we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX). E. coli was transformed with a lambdaZAPII phage cDNA library prepared from mRNA of an esophageal cancer cell line (T.Tn), and IPTG-induced cDNA products were screened for interaction with antibodies in allogeneic sera of patients with esophageal SCC. We identified myomegalin (MMGL, phosphodiesterase 4D interacting protein/PDE4DIP) as a new SEREX antigen for esophageal SCC. Western blot analysis revealed that serum anti-myomegalin antibodies (s-MMGL-Abs) were present in 43 (47%) of 91 patients, but in only one (2.2%) of 45 healthy controls. Of the 21 patients with stage I disease, 8 (38%) were sero-positive. The positive rate of s-MMGL-Abs was greater than those of other conventional tumor markers. Reverse transcription-PCR analysis suggested that alternative splicing from myomegalin variant 1 to variant 5 may explain, in part, the development of s-MMGL-Abs. Although the presence of s-MMGL-Abs was not related to any clinicopathological features of the patients, multivariate analysis indicated that the presence of s-MMGL-Abs was significantly associated with a favorable prognosis. Consequently, s-MMGL-Abs may be a useful tumor marker to diagnose and establish a prognosis in patients with esophageal SCC.